As HBO therapy appears to be effective in suppressing aberrant PFKP activity in NSCLC cell lines as well as aberrant Pfkp activity in murine LLC lung tumors, our findings suggest that HBO therapy may be especially effective in NSCLC tumors (and perhaps other solid tumors) that display enhanced PFKP activity. Here, PFKP is linked to non-small cell lung carcinoma.